Summary & Overview
CPT 81329: SMN1 Deletion Analysis; SMN2 Analysis as Indicated
CPT code 81329 covers laboratory testing to detect deletions in the SMN1 (survival motor neuron 1) gene and may include analysis of the SMN2 gene. This genetic test is clinically important for diagnosing or supporting the diagnosis of spinal muscular atrophy (SMA) and related neuromuscular conditions where SMN1 deletions are etiologic. As molecular diagnostics become more central to precision medicine, accurate coding for SMN1/SMN2 analysis affects access to testing, billing accuracy, and epidemiologic tracking of hereditary neuromuscular disorders nationwide.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for SMN1 deletion testing, the typical service setting and workflow implications for laboratories, and payer coverage landscape summaries. The publication also presents benchmarking and policy-relevant considerations such as coding clarity, site-of-service implications for the technical component, and common modifiers used with laboratory services. Data not available in the input will be noted where applicable.
This summary is intended for laboratory billing staff, compliance officers, and policy analysts seeking a concise national view of CPT code 81329, its clinical role, and the payer environment affecting reimbursement and utilization.
Billing Code Overview
CPT code 81329 describes a molecular diagnostic laboratory test that detects deletions in the survival of motor neuron 1 (SMN1), telomeric, gene and may include analysis of the survival of motor neuron 2 (SMN2), centromeric, gene. The service is a genetic/developmental molecular diagnostic test performed by a clinical laboratory analyst.
Service Type: Molecular diagnostic testing (genetic deletion analysis)
Typical Site of Service: Clinical laboratory / reference lab or hospital laboratory, billed from the performing laboratory (technical component)
Clinical & Coding Specifications
Clinical Context
A neonate or infant with hypotonia, poor feeding, progressive muscle weakness, or a family history of spinal muscular atrophy (SMA) is referred for genetic testing. A pediatric neurologist or geneticist orders molecular diagnostic testing to detect deletions in the survival motor neuron 1 gene (SMN1) with potential analysis of copy number for SMN2. A blood sample (EDTA) is collected in an outpatient clinic, hospital inpatient ward, or neonatal intensive care unit (NICU) and sent to a clinical molecular diagnostics laboratory. The laboratory analyst performs the technical assay — commonly PCR-based copy number analysis, multiplex ligation-dependent probe amplification (MLPA), or quantitative PCR — to detect homozygous deletions or exon-specific deletions in SMN1, and may report SMN2 copy number which informs prognosis and therapeutic considerations. Results are transmitted to the ordering clinician and incorporated into the patient record; the ordering provider interprets results for diagnosis, family counseling, and potential referral for disease-modifying therapies or genetic counseling. Typical sites of service include outpatient specialty clinics, hospital laboratories, and reference molecular diagnostic laboratories supporting NICU and pediatric services.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|